Cell-free vascular grafts: Recent developments and clinical potential

Row, Sindhu; Santandreu, Ana; Swartz, Daniel D.; Andreadis, Stelios T.

doi:10.1142/s2339547817400015

Cited by 22 publications

(32 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using growth factors or biomolecules to overcome thrombus formation and EC recruitment is a strategy for improving the endothelialization of decellularized vascular grafts in vivo. The growth factors include heparin, vascular endothelium growth factor (VEGF), granulocyte-colony stimulating factor (G-CSF), brain-derived growth factor (BDGF), cysteine-rich protein (CYR61; CCN1) and stromal cell-derived factor (SDF-1α), were beneficial for graft patency, an effect of early endothelialization, and perhaps also for graft remodeling [14,15,16,17,18,19,20]. Recellularization before implantation is another route to improve endothelialization of decellularized vascular grafts in vivo.…”

Section: Discussionmentioning

confidence: 99%

Sphingosine-1-phosphate in Endothelial Cell Recellularization Improves Patency and Endothelialization of Decellularized Vascular Grafts In Vivo

Hsia

Lin

Lee

et al. 2019

IJMS

View full text Add to dashboard Cite

Background: S1P has been shown to improve the endothelialization of decellularized vascular grafts in vitro. Here, we evaluated the potential of tissue-engineered vascular grafts (TEVGs) constructed by ECs and S1P on decellularized vascular scaffolds in a rat model. Methods: Rat aorta was decellularized mainly by 0.1% SDS and characterized by histology. Rat ECs, were seeded onto decellularized scaffolds, and the viability of the ECs was evaluated by biochemical assays. Then, we investigated the in vivo patency rate and endothelialization for five groups of decellularized vascular grafts (each n = 6) in a rat abdominal aorta model for 14 days. The five groups included (1) rat allogenic aorta (RAA); (2) decellularized RAA (DRAA); (3) DRAA with S1P (DRAA/S1P); (4) DRAA with EC recellularization (DRAA/EC); and (5) DRAA with S1P and EC recellularization (DRAA/EC/S1P). Results: In vitro, ECs were identified by the uptake of Dil-Ac-LDL. S1P enhanced the expression of syndecan-1 on ECs and supported the proliferation of ECs on decellularized vascular grafts. In vivo, RAA and DRAA/EC/S1P both had 100% patency without thrombus formation within 14 days. Better endothelialization, more wall structure maintenance and less inflammation were noted in the DRAA/EC/S1P group. In contrast, there was thrombus formation in the DRAA, DRAA/S1P and DRAA/EC groups. Conclusion: S1P could inhibit thrombus formation to improve the patency rate of EC-covered decellularized vascular grafts in vivo and may play an important role in the construction of TEVGs.

show abstract

Section: Discussionmentioning

confidence: 99%

Sphingosine-1-phosphate in Endothelial Cell Recellularization Improves Patency and Endothelialization of Decellularized Vascular Grafts In Vivo

Hsia

Lin

Lee

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…For example, grafts comprising decellularized ECM on biodegradable scaffolds have been suggested to serve as readily available TEVGs; these have been tested in a variety of animals models (Dahl et al, 2011) and can exploit recent advances in 3D tissue printing to provide patient-specific grafts (Fukunishi et al, 2017;Best et al, 2018). Cell-free vessel grafts have been generated by allowing cells to secrete ECM for longer periods to more closely mimic the in vivo environment and are then decellularized (Lawson et al, 2016;Row et al, 2017). Furthermore, functionalization of TEVGs with biological signals such as the angiogenic cytokine VEGF have been shown to trigger in situ tissue endothelial regeneration (Koobatian et al, 2016).…”

Section: Regenerative Medicinementioning

confidence: 99%

Aortic “Disease-in-a-Dish”: Mechanistic Insights and Drug Development Using iPSC-Based Disease Modeling

Davaapil

Shetty

Sinha

2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Thoracic aortic diseases, whether sporadic or due to a genetic disorder such as Marfan syndrome, lack effective medical therapies, with limited translation of treatments that are highly successful in mouse models into the clinic. Patient-derived induced pluripotent stem cells (iPSCs) offer the opportunity to establish new human models of aortic diseases. Here we review the power and potential of these systems to identify cellular and molecular mechanisms underlying disease and discuss recent advances, such as gene editing, and smooth muscle cell embryonic lineage. In particular, we discuss the practical aspects of vascular smooth muscle cell derivation and characterization, and provide our personal insights into the challenges and limitations of this approach. Future applications, such as genotype-phenotype association, drug screening, and precision medicine are discussed. We propose that iPSC-derived aortic disease models could guide future clinical trials via "clinical-trials-in-a-dish", thus paving the way for new and improved therapies for patients.

show abstract

“…Alkaline solutions: Sodium hydroxide‐denatures chromosomes, degrade structural components of the ECM, and reduce mechanical properties (Row, Santandreu, Swartz, & Andreadis, ; van Steenberghe et al, )…”

Section: Materials and Techniques For Manufacturing Tevgsmentioning

confidence: 99%

Strategies in cell‐free tissue‐engineered vascular grafts

Yuan

Chen

Liu

et al. 2019

J Biomedical Materials Res

View full text Add to dashboard Cite

Cardiovascular diseases (CVD) remain the leading cause of morbidity and mortality in the world, among which coronary artery diseases (CAD) are the most common type of CVD. Coronary artery bypass grafting (CABG) using autologous vein and artery grafts is the typical surgical intervention for CAD patients. However, for patients whose autologous grafts are not available, there are no appropriate substitutes for vascular grafts. Investigation of tissue-engineered vascular graft (TEVG) has persisted over decades with significant advancement, utilizing different types of biomaterials.In the past two decades, a great number of studies based on cell-seeding strategies were reported. However, limitations of cell-based strategies made clinical application difficult. With the understanding of stem cells and tissue remodeling process, strategies without cell-seeding emerged as potential methods to achieve in situ regeneration.A cell-free graft may recruit host cells and guide their participation in vascular remodeling. The grafts modified by bio-active molecules showed good results in promoting in situ regeneration and exhibited potential to make the vascular grafts off-the-shelf.In this review, the strategies for cell-free TEVG manufacturing were discussed, including the materials for fabricating TEVGs, the methods of functionalization to promote in situ regeneration, the challenges researchers faced in TEVG investigation, and finally the prospects in TEVG design.

show abstract

Cell-free vascular grafts: Recent developments and clinical potential

Cited by 22 publications

References 92 publications

Sphingosine-1-phosphate in Endothelial Cell Recellularization Improves Patency and Endothelialization of Decellularized Vascular Grafts In Vivo

Sphingosine-1-phosphate in Endothelial Cell Recellularization Improves Patency and Endothelialization of Decellularized Vascular Grafts In Vivo

Aortic “Disease-in-a-Dish”: Mechanistic Insights and Drug Development Using iPSC-Based Disease Modeling

Strategies in cell‐free tissue‐engineered vascular grafts

Contact Info

Product

Resources

About